Jason Rifkin

Jason Rifkin is a member of MAX BioPharma’s Business Advisory Board. Jason is currently President & CEO of PhageNova Bio. As a biotechnology and medical device executive with extensive experience in developmental stage life sciences companies. Jason has managed all aspects of company operations including clinical operations, business development, technology licensing, and capital raising. Jason also serves as President of PreScience Labs, an early-stage oncology company where he oversees the build-up of a Phase I clinical trial program. Prior to joining PreScience, Jason held a number of executive positions in which he oversaw the transition of Delcath Systems – a specialty pharmaceutical and medical device company focused on oncology — from a developmental stage company to a publicly-traded commercial operation. Before joining Delcath, he practiced law with Fox Rothschild, serving as an associate in the Corporate Department-Pharmaceuticals and Biotechnology Group. Jason received a Bachelor’s Degree from The University of Pennsylvania, a Law Degree from Northeastern University School of Law and a Master's of Biotechnology from The University of Pennsylvania, School of Engineering and Applied Sciences.